

Web Table 1. SNPs under study in the cell cycle control genes, the Shanghai Endometrial Cancer Study, China, 1997-2003.

No.	Genes	SNP	Alleles ^a	Role	Position ^b	Chromosome	MAF ^c	Genotype frequency ^d			P value ^e	Het OR 95% CI ^f		Hom OR 95% CI ^g		P trend
								AA	AB	BB		OR	95% CI	OR	95% CI	
1	<i>CCNB1</i>	rs352626	T/C	Promoter	68497959	Chr5	47.64	28.16	48.40	23.44	0.107	1.10	0.89,1.37	1.01	0.78,1.30	0.922
2		rs350104	C/T	Promoter	68498194	Chr5	31.60	46.47	43.86	9.67	0.503	1.21	1.00,1.47	1.19	0.86,1.64	0.074
3		rs2069433	C/T	Intron	68503263	Chr5	7.28	85.89	13.67	0.44	1.000	0.79	0.60,1.02	0.35	0.08,1.46	0.030
4	<i>CCND1</i>	rs649392	G/A	Intron	69173974	Chr11	11.23	76.39	22.13	1.48	<0.001	0.96	0.77,1.20	0.75	0.35,1.60	0.518
5	<i>CCNE1</i>	rs3218055	G/A	Intron	35002719	Chr19	14.38	73.36	24.52	2.12	0.631	0.81	0.66,1.00	0.91	0.48,1.71	0.080
6		rs1406	T/G	3'UTR	35006952	Chr19	32.67	45.38	43.90	10.72	0.481	1.04	0.86,1.26	0.83	0.61,1.14	0.510
7	<i>CDK2</i>	rs2069415	A/G	3'UTR	54652246	Chr12	14.53	72.76	25.42	1.82	0.632	0.90	0.73,1.11	0.86	0.44,1.70	0.297
8		rs773107	G/A	3'flanking	54655773	Chr12	7.46	85.47	14.14	0.39	0.083	1.06	0.82,1.38	6.09	0.73,51.0	0.306
9		rs773108	G/A	3'flanking	54656178	Chr12	24.14	57.83	36.06	6.11	1.000	0.91	0.75,1.10	0.97	0.66,1.43	0.469
10	<i>CDK4</i>	rs2069502	G/A	Intron	56430932	Chr12	36.37	40.29	46.70	13.02	0.451	0.99	0.81,1.20	1.05	0.79,1.40	0.836
11		rs2270777	A/G	Intron	56431423	Chr12	15.37	71.58	26.11	2.32	0.810	1.00	0.81,1.23	0.82	0.44,1.52	0.762
12		rs2072052	A/C	Promoter	56432986	Chr12	36.58	39.96	46.92	13.12	0.332	0.99	0.81,1.20	1.07	0.80,1.43	0.760
13	<i>CDK6</i>	rs4272	G/A	3'UTR	91881480	Chr7	10.77	79.40	19.66	0.94	0.533	0.82	0.65,1.04	0.70	0.27,1.83	0.074
14		rs42031	T/A	3'UTR	91882047	Chr7	5.65	89.05	10.60	0.35	0.569	0.87	0.65,1.16	1.61	0.28,9.18	0.458
15		rs42041	G/C	Intron	91891395	Chr7	2.22	95.57	4.43	0.00	1.000	0.95	0.61,1.50	-	-	-
16		rs2040494	C/T	Intron	91901556	Chr7	20.18	63.39	32.86	3.75	0.090	0.96	0.79,1.16	1.46	0.89,2.39	0.598
17		rs2237570	T/A	Intron	91902905	Chr7	8.65	83.47	15.76	0.77	0.842	1.04	0.81,1.34	0.90	0.30,2.67	0.847
18		rs2237572	T/C	Intron	91904911	Chr7	21.29	64.11	29.20	6.69	0.003	1.01	0.82,1.23	1.28	0.88,1.86	0.346
19		rs2282978	C/T	Intron	91909061	Chr7	11.30	78.73	19.94	1.33	1.000	0.79	0.63,0.99	0.75	0.34,1.68	0.040
20		rs2282979	C/T	Intron	91909644	Chr7	10.81	79.57	19.25	1.18	0.887	0.80	0.64,1.01	0.67	0.28,1.57	0.042
21		rs10225965	C/T	Intron	91918229	Chr7	29.69	49.33	41.94	8.72	0.597	0.92	0.76,1.12	0.95	0.68,1.32	0.498
22		rs2282981	T/C	Intron	91921377	Chr7	16.31	69.64	28.09	2.27	0.032	0.87	0.71,1.07	1.48	0.79,2.77	0.635
23		rs2282983	C/T	Intron	91924014	Chr7	27.33	52.39	40.57	7.04	0.223	0.85	0.70,1.02	0.83	0.58,1.20	0.088

24		rs11773884	G/A	Intron	91929774	Chr7	15.94	70.33	27.45	2.22	0.196	0.95	0.78,1.17	1.24	0.66,2.32	0.974
25		rs2282985	C/G	Intron	91940068	Chr7	49.60	25.26	50.27	24.47	0.314	0.87	0.70,1.09	0.94	0.72,1.21	0.615
26		rs2282986	C/T	Intron	91944196	Chr7	33.56	43.52	45.84	10.65	0.620	1.10	0.91,1.33	1.06	0.76,1.44	0.474
27		rs2301556	A/G	Intron	91945238	Chr7	14.41	72.96	25.26	1.78	0.123	0.93	0.76,1.15	1.48	0.73,2.98	0.992
28		rs7781436	C/T	Intron	91962403	Chr7	3.71	92.72	7.13	0.15	0.620	1.24	0.87,1.76	-	-	-
29		rs11981129	T/C	Intron	91968701	Chr7	48.18	26.85	49.95	23.20	0.448	0.95	0.77,1.18	1.10	0.85,1.42	0.514
30		rs3802079	A/G	Intron	91975131	Chr7	33.30	44.33	44.73	10.94	0.888	1.02	0.84,1.24	1.03	0.76,1.40	0.815
31		rs2079147	G/A	Intron	91977026	Chr7	12.62	76.33	22.09	1.58	1.484	0.88	0.71,1.10	1.40	0.67,2.93	0.615
32		rs10254840	G/A	Intron	91978059	Chr7	47.78	27.83	48.77	23.40	0.797	0.97	0.78,1.21	1.09	0.85,1.41	0.536
33		rs2282991	T/A	Intron	91989732	Chr7	7.17	86.16	13.35	0.49	1.000	0.87	0.66,1.13	0.69	0.19,2.55	0.243
34		rs10228493	C/T	Intron	92005048	Chr7	15.01	72.01	25.97	2.02	0.516	1.05	0.85,1.29	1.15	0.60,2.20	0.564
35		rs17164769	C/T	Intron	92018032	Chr7	15.75	71.12	26.27	2.61	1.000	1.02	0.83,1.25	1.27	0.72,2.25	0.559
36		rs2282993	G/A	Intron	92036132	Chr7	15.83	71.05	26.24	2.71	1.000	0.99	0.80,1.21	1.25	0.71,2.20	0.747
37		rs3802074	G/A	Intron	92041142	Chr7	6.11	88.12	11.54	0.35	0.169	0.88	0.66,1.17	-	-	-
38		rs3731303	A/G	Intron	92048510	Chr7	15.35	72.40	24.49	3.10	0.467	0.95	0.77,1.17	1.29	0.76,2.20	0.853
39		rs445	T/C	Intron	92053021	Chr7	34.69	42.29	46.04	11.67	0.209	1.00	0.82,1.21	1.22	0.90,1.65	0.326
40		rs1005346	G/A	Intron	92068156	Chr7	12.39	76.90	21.43	1.67	0.772	0.87	0.70,1.09	1.11	0.54,2.26	0.364
41		rs17164786	C/T	Intron	92077947	Chr7	5.89	88.77	10.67	0.55	0.562	0.87	0.65,1.18	1.55	0.43,5.59	0.604
42		rs10246604	A/C	Intron	92093944	Chr7	7.91	85.17	13.84	0.99	0.659	0.91	0.70,1.18	1.58	0.61,4.13	0.847
43		rs3731268	A/G	Intron	92104894	Chr7	6.04	88.41	11.09	0.49	1.000	0.85	0.64,1.13	1.87	0.47,7.52	0.508
44		rs929244	A/G	Promoter	92110956	Chr7	9.13	82.88	15.98	1.14	1.000	0.90	0.70,1.16	1.49	0.61,3.66	0.775
45	<i>CDKN1A</i>	rs3829963	A/C	Promoter	36752362	Chr6	42.08	34.49	46.86	18.65	0.027	1.01	0.82,1.24	0.79	0.61,1.03	0.129
46		rs3176343	A/G	Intron	36758245	Chr6	31.16	48.02	41.63	10.35	0.092	1.06	0.87,1.28	0.89	0.65,1.22	0.797
47		rs12207548	C/T	3'flanking	36764234	Chr6	41.92	34.09	47.98	17.93	0.117	1.25	1.02,1.53	1.10	0.85,1.44	0.249
48		rs12528248	A/G	3'flanking	36764360	Chr6	45.32	30.89	47.59	21.53	0.018	1.09	0.89,1.35	0.83	0.65,1.07	0.237
49		rs12191972	C/T	3'flanking	36766720	Chr6	12.81	76.20	21.98	1.82	0.020	1.17	0.94,1.45	0.52	0.26,1.05	0.839
50	<i>CDKN1B</i>	rs12229100	T/C	Promoter	12757103	Chr12	32.57	44.77	45.32	9.91	0.240	0.98	0.81,1.18	1.01	0.73,1.38	0.930

51	rs11055027	C/G	Promoter	12758748	Chr12	18.24	66.83	29.86	3.31	0.731	1.21	0.99,1.48	1.89	1.12,3.19	0.006	
52	rs3759216	A/G	Promoter	12759353	Chr12	43.66	31.80	49.06	19.13	0.376	0.76	0.62,0.93	0.73	0.56,0.94	0.008	
53	rs3759217	T/C	Promoter	12759719	Chr12	4.15	91.91	7.89	0.20	0.649	1.13	0.80,1.58	0.90	0.12,6.58	0.525	
54	rs34330	T/C	5'UTR	12761962	Chr12	49.75	25.85	48.79	25.36	0.184	1.33	1.06,1.66	1.51	1.16,1.94	0.002	
55	rs4251697	A/G	3'UTR	12765729	Chr12	13.37	74.98	23.30	1.72	0.780	1.06	0.85,1.31	0.98	0.49,1.97	0.679	
56	rs7330	C/A	3'UTR	12766184	Chr12	11.95	77.34	21.43	1.23	0.541	1.02	0.82,1.28	1.34	0.59,3.06	0.633	
57	rs1420023	G/C	3'flanking	12767378	Chr12	12.35	76.74	21.83	1.43	0.870	1.19	0.95,1.48	1.67	0.77,3.61	0.055	
58	rs34322	C/T	3'flanking	12770837	Chr12	48.35	27.47	48.37	24.16	0.492	0.84	0.67,1.04	0.73	0.57,0.94	0.015	
59	<i>CDKN2A</i>	rs3731257	C/T	3'flanking	21956221	Chr9	49.48	26.40	48.23	25.37	1.000	0.91	0.73,1.13	1.06	0.82,1.37	0.654
60		rs3731239	C/T	Intron	21964218	Chr9	13.58	74.96	22.92	2.12	0.590	0.91	0.73,1.13	0.97	0.52,1.81	0.464
61		rs4074785	A/G	Intron	21971583	Chr9	12.39	77.14	20.94	1.92	0.093	1.18	0.95,1.48	0.99	0.50,1.95	0.230
62		rs3731217	G/T	Intron	21974661	Chr9	20.10	64.48	30.84	4.68	0.326	0.99	0.81,1.20	1.00	0.65,1.55	0.930
63		rs7036656	C/T	Intron	21980457	Chr9	22.37	60.73	33.79	5.48	0.723	0.97	0.80,1.18	1.11	0.74,1.67	0.923
64		rs3218020	T/C	Promoter	21987872	Chr9	47.49	27.99	49.04	22.97	0.842	1.01	0.81,1.25	1.05	0.81,1.35	0.744
65		rs2811712	G/A	Promoter	21988035	Chr9	22.19	61.03	33.55	5.42	0.858	0.89	0.74,1.09	1.05	0.70,1.58	0.543

a. Minor allele is bolded.

b. Chromosome position based on NCBI build 35.

c. Minor allele frequency for each SNP.

d. For each SNP, AA, major allele homozygote, AB, heterozygote, BB, minor allele homozygote.

e. P value is the probability of the Chi-square test for Hardy-Weinberg disequilibrium among controls.

f. Heterozygous odds ratio (95% confidence interval).

g. Homozygous odds ratio (95% confidence interval).